|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
3/15/2013 10:23:46 AM
STOCKHOLM--(BUSINESS WIRE)--Regulatory News: RaySearch Laboratories AB (STO:RAYB) announces that version 3.5 of RaySearch's RayStation® treatment planning system has been released for clinical use in the European Union, USA, Japan and Australia, and is pending regulatory approval in Canada, China, New Zealand and South Korea. The new version includes a wide range of new features and improvements. With RayStation® 3.5 RaySearch releases state of-the-art tools for treatment planning of radiation therapy with electrons and protons, complementing RayStation’s extensive tools for planning and optimization of radiation therapy with photons. Proton Beam Design is a brand new module in RayStation® that contains tools for treatment planning of double scattered and uniformly scanned protons, such as a clinically approved Pencil Beam dose engine and automatic generation of treat-and-protect beams. This is the first clinical release of proton planning functionality in RayStation®, to be followed by many others, such as Pencil Beam Scanning techniques and Monte Carlo dose calculations. Electron Beam Design is another entirely new module that includes a Monte Carlo dose engine for electron radiation therapy and tools for manual editing of beams similar to how it is done in the 3D-CRT module. The functionality for Proton Beam Design and Electron Beam Design is available for installation in the European Union, Japan and Australia but is pending regulatory clearance in USA.
|
|
|
|
|
|
|
|
|
|
|